Jenny Bergqvist

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BRITISH JOURNAL OF CANCER. 2023;129(1):61-71
Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women
Hammarstroem M; Gabrielson M; Crippa A; Discacciati A; Eklund M; Lundholm C; Baecklund M; Wengstroem Y; Borgquist S; Bergqvist J; Eriksson M; Tapia J; Czene K; Hall P
Article: INTERNATIONAL JOURNAL OF CANCER. 2023;152(11):2362-2372
Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women
Gabrielson M; Hammarstrom M; Baecklund M; Bergqvist J; Lang K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Article: SUPPORTIVE CARE IN CANCER. 2022;30(9):7721-7730
Equal receipt of specialized palliative care in breast and prostate cancer: a register study
Bergqvist J; Hedman C; Schultz T; Strang P
Article: ONCOLOGIST. 2022;27(7):E597-E600
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial
Backlund M; Eriksson M; Gabrielson M; Hammarstrom M; Quay S; Bergqvist J; Hellgren R; Czene K; Hall P
Article: CANCERS. 2021;13(15):3707
'Palliative-D'-Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial
Frankling MH; Klasson C; Sandberg C; Nordstrom M; Warnqvist A; Bergqvist J; Bergman P; Bjorkhem-Bergman L
Article: SUPPORTIVE CARE IN CANCER. 2021;29(1):491-497
Patient interactive digital support for women with adjuvant endocrine therapy in order to increase compliance and quality of life
Bergqvist J; Lundstrom S; Wengstrom Y
Article: JOURNAL OF PALLIATIVE MEDICINE. 2020;23(1):67-73
The Impact of Integrated Home Palliative Care Services on Resource Use and Place of Death
Bergqvist J; Ljunggren G
Article: JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2019;57(4):746-752
Breast Cancer Patients' Preferences for Truth Versus Hope Are Dynamic and Change During Late Lines of Palliative Chemotherapy
Bergqvist J; Strang P
Article: JOURNAL OF NEURO-ONCOLOGY. 2018;139(3):599-608
The effects of clinical and sociodemographic factors on survival, resource use and lead times in patients with high-grade gliomas: a population-based register study
Bergqvist J; Iderberg H; Mesterton J; Henriksson R
Article: BMJ SUPPORTIVE AND PALLIATIVE CARE. 2017;7(4):458-463
Vitamin D supplementation to palliative cancer patients: protocol of a double-blind, randomised controlled trial 'Palliative-D'
Helde-Frankling M; Bergqvist J; Klasson C; Nordstrom M; Hoijer J; Bergman P; Bjorkhem-Bergman L
Article: ACTA ONCOLOGICA. 2017;56(10):1258-1264
Does palliative chemotherapy provide a palliative effect on symptoms in late palliative stages? An interview study with oncologists
Strang P; Bergqvist J
Article: ACTA ONCOLOGICA. 2017;56(9):1168-1174
The will to live - breast cancer patients perceptions' of palliative chemotherapy
Bergqvist J; Strang P
Article: ACTA ONCOLOGICA. 2017;56(3):405-414
Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study
Bergqvist J; Iderberg H; Mesterton J; Bengtsson N; Wettermark B; Henriksson R
Article: PLOS ONE. 2017;12(8):e0184208
Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study
Helde-Frankling M; Hoijer J; Bergqvist J; Bjorkhem-Bergman L
Article: CANCERS. 2016;8(9):84
Antibiotic Treatment in End-of-Life Cancer Patients-A Retrospective Observational Study at a Palliative Care Center in Sweden
Helde-Frankling M; Bergqvist J; Bergman P; Bjorkhem-Bergman L
Article: PLOS ONE. 2015;10(5):e0128223
Low Vitamin D Levels Are Associated with Higher Opioid Dose in Palliative Cancer Patients - Results from an Observational Study in Sweden
Bergman P; Sperneder S; Hoijer J; Bergqvist J; Bjorkhem-Bergman L
Article: BREAST CANCER RESEARCH AND TREATMENT. 2013;139(3):751-758
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
Bjohle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Soderberg M; Sundquist M; Walz TM; Ferno M; Bergh J; Hatschek T
Article: FAMILIAL CANCER. 2010;9(3):263-265
RASSF1A polymorphism in familial breast cancer
Bergqvist J; Latif A; Roberts SA; Hadfield KD; Lalloo F; Howell A; Evans DG; Newman WG
Article: MEDICAL ONCOLOGY. 2009;26(4):480-490
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Article: ANNALS OF ONCOLOGY. 2007;18(5):845-850
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome
Bergqvist J; Ohd JF; Smeds J; Klaar S; Isola J; Nordgren H; Elmberger GP; Hellborg H; Bjohle J; Borg A-L; Skoog L; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2006;42(8):1104-1112
Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen
Bergqvist J; Elmberger G; Ohd J; Linderholm B; Bjohle J; Hellborg H; Nordgren H; Borg A-L; Skoog L; Bergh J
Article: ANNALS OF ONCOLOGY. 2005;16(5):743-748
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
Andersson J; Larsson L; Klaar S; Holmberg L; Nilsson J; Inganäs M; Carlsson G; Öhd J; Rudenstam CM; Gustavsson B; Bergh J
Article: APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY. 2004;12(1):14-20
HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components
Andersson J; Linderholm B; Bergh J; Elmberger G
Article: EUROPEAN JOURNAL OF CANCER. 2004;40(1):33-42
Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment
Linderholm B; Andersson J; Lindh B; Beckman L; Erlanson M; Edin K; Tavelin B; Grankvist K; Henriksson R
Article: ACTA ONCOLOGICA. 2002;41(3):276-281
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin®) on a named patient basis in Sweden
Andersson J; Linderholm B; Greim G; Lindh B; Lindman H; Tennvall J; Tennvall-Nittby L; Pettersson-Sköld D; Sverrisdottir A; Söderberg M; Klaar S; Bergh J
Visa fler

Alla övriga publikationer

Corrigendum: BREAST. 2008;17(3):319
"How to treat male breast cancer" (vol 16S2, pg S147, 2007)
Czene K; Bergqvist J; Hall P; Bergh J
Published conference paper: BREAST. 2007;16:S147-S154
How to treat male breast cancer
Kamila C; Jenny B; Per H; Jonas B
Thesis / dissertation: 2006
HER2 and TP53 in human breast cancer : studies of methods and prognostic value
Bergqvist, Jenny
Published conference paper: ACTA ONCOLOGICA. 2000;39(3):319-326
Can axillary dissection be avoided by improved molecular biological diagnosis?
Lindahl T; Engel G; Ahlgren J; Klaar S; Bjöhle J; Lindman H; Andersson J; von Schoultz E; Bergh J

Anställningar

Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2022-2025

Examina och utbildning

Docent, onkologi, Karolinska Institutet, 2020
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2006

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI